Pearl Therapeutics gathers $8M to treat breathing disorders

Pearl Therapeutics, a Redwood City, Calif.-based developer of inhaled drugs to treat respiratory diseases like COPD and asthma, just landed $8 million in venture debt from Oxford Finance and Silicon Valley Bank to expand its product line.

The company licensed particle-based technology from San Carlos, Calif.-based… Continue Reading

Pearl Therapeutics ups its first round funding

Pearl Therapeutics, a biopharmaceutical company, has upped its first round of funding to $33.5 million after an additional $18 million investment, according to VentureWire.

New investor Nektar Therapeutics joins all of the company’s previous investors including Clarus Ventures, New Leaf Ventures and 5AM Ventures in this… Continue Reading

Life-science briefing: Friday, April 4, 2008

TODAY’S HEADLINES:

IlluminOss Medical gets $11M for bone-fracture devices (peHUB)
Contract researcher Crown Bioscience takes in funding (release)

IlluminOss Medical gets $11M for bone-fracture devices — East Providence, R.I.-based IlluminOss Medical, a medical-device startup, raised $11 million in a second funding round, peHUB reports. Backers included New Leaf… Continue Reading

Life sciences briefing: Wednesday, Oct. 3, 2007

Life sciences briefing: Wednesday, Oct. 3, 2007

Featured companies: Aveo Pharmaceuticals, Aviir, deltaDot, Origen Therapeutics

Heart-diagnostic maker Aviir raises $11.3M — Palo Alto, Calif.-based Aviir, a biotech developing cardiovascular diagnostics based on Stanford research, raised $11.3 million of an expected $25 million second funding round, PE Hub reports. The news is presumably from one… Continue Reading

Life sciences briefing: Thursday, Sept. 6, 2007

Life sciences briefing: Thursday, Sept. 6, 2007

Featured companies: Cyntellect, Lectus Therapeutics, NeoMatrix, Nexstim, Pearl Therapeutics, Proteon Therapeutics, SupplyScape

(UPDATED at 10am PT: See below.)

Airway-disease specialist Pearl Therapeutics raises $15.5M — Redwood City, Calif.-based Pearl Therapeutics, a drug-formulation company focused on respiratory disease, raised $15.5 million in a first funding round. Investors included New Leaf… Continue Reading